GeneDx Holdings (GeneDx Holdings) Market Cap : $288.7 Mil (As of Apr. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GeneDx Holdings's share price for the quarter that ended in Dec. 2023 was $2.75. GeneDx Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 26.0 Mil. Therefore, GeneDx Holdings's market cap for the quarter that ended in Dec. 2023 was $71.4 Mil.

GeneDx Holdings's quarterly market cap declined from Jun. 2023 ($153.5 Mil) to Sep. 2023 ($94.2 Mil) and declined from Sep. 2023 ($94.2 Mil) to Dec. 2023 ($71.4 Mil).

GeneDx Holdings's annual market cap declined from Dec. 2021 ($1,082.2 Mil) to Dec. 2022 ($102.5 Mil) and declined from Dec. 2022 ($102.5 Mil) to Dec. 2023 ($71.4 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GeneDx Holdings's Enterprise Value for Today is $278.3 Mil.

GeneDx Holdings Market Cap Historical Data

The historical data trend for GeneDx Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Market Cap Chart

GeneDx Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

1,082.21

102.49

71.44

GeneDx Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial										102.49	291.41	153.54	94.19	71.44

Competitive Comparison of GeneDx Holdings's Market Cap

For the Health Information Services subindustry, GeneDx Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneDx Holdings's Market Cap Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Market Cap falls into.

GeneDx Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

GeneDx Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$2.75	*	25.9789
	=	$71.4

GeneDx Holdings's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$2.75	*	25.9789
	=	$71.4

GeneDx Holdings (NAS:WGS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

GeneDx Holdings Market Cap Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneDx Holdings (GeneDx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902

Website

https://www.genedx.com

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.

Executives

Kareem Saad	officer: Chief Business Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland	director, officer: Chief Executive Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley	officer: Chief Financial Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister	director, 10 percent owner	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White	officer: Chief People Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp	director, 10 percent owner	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp	director, 10 percent owner	667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137